Scholfield Daniel W, Fitzgerald Conall W R, Boe Lillian A, Eagan Alana, Levyn Helena, Xu Bin, Tuttle R Michael, Fagin James A, Shaha Ashok R, Shah Jatin P, Wong Richard J, Patel Snehal G, Ghossein Ronald, Ganly Ian
Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ann Surg Oncol. 2024 Sep;31(9):5525-5536. doi: 10.1245/s10434-024-15500-9. Epub 2024 Jun 7.
Diffuse sclerosing papillary thyroid carcinoma (DSPTC) is an aggressive histopathologic subtype of papillary thyroid carcinoma. Correlation between genotype and phenotype has not been comprehensively described. This study aimed to describe the genomic landscape of DSPTC comprehensively using next-generation sequencing (NGS), analyze the prognostic implications of different mutations, and identify potential molecular treatment targets.
Tumor tissue was available for 41 DSPTC patients treated at Memorial Sloan Kettering Cancer Center between 2004 and 2021. After DNA extraction, NGS was performed using the Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets platform, which sequences 505 critical cancer genes. Clinicopathologic characteristics were compared using the chi-square test. The Kaplan-Meier method and log-rank statistics were used to compare outcomes.
The most common mutation was RET fusion, occurring in 32% (13/41) of the patients. Other oncologic drivers occurred in 68% (28/41) of the patients, including 8 BRAF mutations (20%) and 4 USP8 mutations (10%), which have not been described in thyroid malignancy previously. Patients experienced RET fusion-positive tumors at a younger age than other drivers, with more aggressive histopathologic features and more advanced T stage (p = 0.019). Patients who were RET fusion-positive had a significantly poorer 5-year recurrence-free survival probability than those with other drivers (46% vs 84%; p = 0.003; median follow-up period, 45 months). In multivariable analysis, RET fusion was the only independent risk factor for recurrence (hazard ratio [HR], 7.69; p = 0.017).
Gene-sequencing should be strongly considered for recurrent DSPTC due to significant prognostic and treatment implications of RET fusion identification. The novel finding of USP8 mutation in DSPTC requires further investigation into its potential as a driver mutation.
弥漫性硬化性乳头状甲状腺癌(DSPTC)是乳头状甲状腺癌的一种侵袭性组织病理学亚型。基因型与表型之间的相关性尚未得到全面描述。本研究旨在使用下一代测序(NGS)全面描述DSPTC的基因组图谱,分析不同突变的预后意义,并确定潜在的分子治疗靶点。
2004年至2021年间在纪念斯隆凯特琳癌症中心接受治疗的41例DSPTC患者有肿瘤组织可用。提取DNA后,使用纪念斯隆凯特琳可操作癌症靶点综合突变分析平台进行NGS,该平台对505个关键癌症基因进行测序。使用卡方检验比较临床病理特征。采用Kaplan-Meier法和对数秩统计比较结果。
最常见的突变是RET融合,发生在32%(13/41)的患者中。其他肿瘤驱动因素发生在68%(28/41)的患者中,包括8个BRAF突变(20%)和4个USP8突变(10%),这些突变此前在甲状腺恶性肿瘤中尚未有描述。RET融合阳性肿瘤患者的年龄比其他驱动因素患者更小,具有更具侵袭性的组织病理学特征和更晚期的T分期(p = 0.019)。RET融合阳性患者的5年无复发生存概率显著低于其他驱动因素患者(46%对84%;p = 0.003;中位随访期45个月)。在多变量分析中,RET融合是复发的唯一独立危险因素(风险比[HR],7.69;p = 0.017)。
由于RET融合鉴定对复发DSPTC具有重要的预后和治疗意义,因此对于复发的DSPTC应强烈考虑进行基因测序。DSPTC中USP8突变这一新发现需要进一步研究其作为驱动突变的潜力。